Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

29.28 +0.26 (+0.90%)

Streaming Delayed Price Updated: 3:04 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’

June 22, 2023

From Genmab

Via Business Wire

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

June 09, 2023

From Genmab

Via Business Wire

Expert Ratings for Genmab ↗

June 06, 2023

Via Benzinga

Recap: Genmab Q1 Earnings ↗

May 10, 2023

Via Benzinga

How To Attend Genmab Q1 2023 Earnings Conference Call ↗

May 08, 2023

Via Benzinga

Price Over Earnings Overview: Genmab ↗

April 27, 2023

Via Benzinga

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

May 25, 2023

From Genmab A/S

Via Business Wire

FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients ↗

May 19, 2023

The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...

Via Benzinga

EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

May 19, 2023

From Genmab A/S

Via Business Wire

Analyst Ratings for Genmab ↗

April 20, 2023

Via Benzinga

P/E Ratio Insights for Genmab ↗

April 11, 2023

Via Benzinga

This Foreboding Sign Looms Over Genmab's Chart ↗

March 31, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About Genmab ↗

March 01, 2023

Via Benzinga

Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst ↗

April 24, 2023

Via Benzinga

Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

April 17, 2023

On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.

Via Investor's Business Daily

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

April 17, 2023

From Genmab

Via Business Wire

Earnings Outlook For Genmab ↗

February 21, 2023

Via Benzinga

Alkermes Stock Sees Rising Relative Price Strength ↗

February 17, 2023

The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.

Via Investor's Business Daily

Moderna Stock Getting Closer To Key Technical Benchmark ↗

February 10, 2023

On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.

Via Investor's Business Daily

Anavex Life Sciences Stock Shows Improved Price Strength Rating ↗

February 07, 2023

Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.

Via Investor's Business Daily

Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 19, 2023

On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.

Via Investor's Business Daily

Vertex Pharmaceuticals Stock Sees Rising Relative Strength ↗

January 11, 2023

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

3 Biotech Companies to Watch in 2023 ↗

January 06, 2023

These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.

Via InvestorPlace

Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

December 21, 2022

From Genmab A/S

Via Business Wire

Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗

December 14, 2022

See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.

Via Investor's Business Daily

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

December 11, 2022

From Genmab A/S

Via Business Wire

Our 7 Top Biotech Stock Picks for 2023 ↗

December 09, 2022

Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.

Via InvestorPlace

BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating ↗

December 08, 2022

On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.

Via Investor's Business Daily

3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗

December 08, 2022

These companies have long runways of growth ahead

Via The Motley Fool

Is AbbVie Stock a Buy Now? ↗

December 06, 2022

The pharmaceutical company prepared well as Humira approaches its patent cliff next year.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Genmab A/S - American Depositary Shares (NQ:GMAB)

All News about Genmab A/S - American Depositary Shares

Starting at /week.